Pluristyx, Inc., panCELLa, and Implant Therapeutics announced they have entered into a manufacturing and distribution strategic alliance that offers cell therapy companies streamlined access to the next generation of safe, universal, cost-effective, “off-the-shelf” iPSCs.
[Pluristyx, Inc.]
7992332
{7992332:BBBBBBBB}
apa
50
1
171101
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
